Information  X 
Enter a valid email address

Blancco Tech Grp PLC (BLTG)

  Print          Annual reports

Monday 03 June, 2019

Blancco Tech Grp PLC

Capital Markets Event

RNS Number : 8201A
Blancco Technology Group PLC
03 June 2019
 

3 June 2019

 

Blancco Technology Group PLC

("Blancco" or the "Group")

 

Capital Markets Event

 

Blancco Technology Group (AIM: BLTG), a leading global provider of mobile device diagnostics and secure data erasure solutions, today hosts a Capital Markets Event with presentations from senior management. 

 

The event will provide an overview of the Group's strategy and large-scale opportunities in its three core end markets; Mobile, Data Centre / Enterprise and IT Asset Disposition (ITAD), as well as further insight into its growing international customer base and partnerships with tier 1 multinational technology distributors.

 

Post the event, a webcast will be available via the following link:

https://webcasting.buchanan.uk.com/broadcast/5cee9dd5bfcf9b13b48e285b 

 

Presentations will commence at 14:00 UK time.  No new trading or financial information will be disclosed.

 

For further information:

 

Blancco Technology Group Plc

Matt Jones, Chief Executive Officer

Adam Moloney, Chief Financial Officer

 

via Buchanan

Peel Hunt LLP (Nominated Adviser and Broker)

Edward Knight

Peter Stewart

Nick Prowting

 

+44 (0) 20 7418 8900

 

Panmure Gordon (UK) Limited (Joint Broker)

Dominic Morley, Corporate Finance

Charles Leigh Pemberton, Corporate Broking

 

+44 (0) 20 7886 2500

Buchanan

Henry Harrison-Topham              

Chris Lane

Stephanie Watson

 

+44 (0) 20 7466 5000

[email protected]

 

About Blancco

Blancco Technology Group plc is a leading global provider of mobile device diagnostics and secure data erasure solutions.  For more information, please visit www.blanccotechnologygroup.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUAUVRKWAVOAR

a d v e r t i s e m e n t